The one day conference, ‘Pharmaceutical Sensors of the Future: High Street or High Value?’, combined presentations, workshops and debate to explore innovative ways to monitor patients and collect and analyse data to create more intelligent clinical datasets.
Bruce Hellman, CEO and Co-founder of uMotif Digital Health, said, “This event added real value, drawing on experience from the healthcare sector but also looking at how we can learn lessons from other industries to address the importance of data-led strategies and the ethical issues linked with this approach. The agenda delivered valuable information to help accelerate our collective learning and knowledge.” Other speakers included Matthew Heasley from GlaxoSmithKline, Paul Gershlick and Naomi Pryde from Matthew Arnold & Baldwin and Timothy d’Estrube from Accenture Analytics Health & Public Services.
The afternoon workshops allowed delegates to put into practice their understanding of the fundamental points raised through the presentations. Timothy d’Estrube of Accenture commented: “The workshops provided a stimulating and thought-provoking environment to challenge some of the ideas raised by the speakers. It was an excellent forum for networking and pushing technological boundaries with like-minded people.” The four workshops fell under the following themes: The Future of Sensors - A Real Commercial Perspective; Sensors that are Operational in the Pharmaceutical Arena; The True Cost of Data Collection; and Devising Business Value from Analytics.
The event culminated with a panel session that gave the opportunity to further explore some of the issues raised, such as the utilisation of sensors by pharmaceutical giants, achieving clinical acceptance and concerns with remote monitoring, specifically given the increasing availability of low cost off-the-shelf sensors. James Weatherall of AstraZeneca and Richard Bailey of EE joined the line-up prominent panellists.
Soraya Jones, Chief Executive, CW said: “This event is always very popular and a great reflection of the strong relationship we have with One Nucleus.” Harriet Fear, CEO of One Nucleus, continued: “Drawing on the resources of both our organisations we are able to provide a vibrant arena for learning, discussion, debate and networking.”
The event was sponsored by Plextek Consulting and supported by the Eastern Academic Health Science Network and Health Enterprise East. The Wireless Healthcare SIG is championed by Rob Blake of Philips Research UK, Peter Ferguson of Accenture, Collette Johnson of Plextek and Paul Winter of TTP.
For more information please visit the Cambridge Wireless website: www.cambridgewireless.co.uk/events
About Cambridge Wireless (CW)
CW is the leading international community for companies involved in the research, development and application of wireless & mobile, internet, semiconductor and software technologies. With 400 members from major network operators and device manufacturers to innovative start-ups and universities, CW stimulates debate and collaboration, harnesses and shares knowledge, and helps to build connections between academia and industry. CW's 19 Special Interest Groups (SIGs) provide its members with a dynamic forum where they can network with their peers, track the latest technology trends and business developments and position their organisations in key market sectors. CW also organises the annual Future of Wireless International Conference and Discovering Start-ups competition along with other high-quality industry networking events and dinners. With headquarters at the heart of Cambridge, UK, CW partners with other international industry clusters and organisations to extend its reach and remain at the forefront of global developments and business opportunities. For more information, please visit www.cambridgewireless.co.uk
For Cambridge Wireless please contact:
01223 967101, email@example.com
About One Nucleus
One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe’s largest life science and healthcare cluster.
Vision: For One Nucleus and our members to be the top European life science and healthcare network
Mission: We will achieve this by maximising the global competitiveness of our members.
Established in 1997, One Nucleus is a not-for-profit membership organisation located in Cambridge. We have over 470 organisations as members, including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers. One Nucleus’ mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means them being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means them delivering exceptional services that significantly enhance the business performance of their clients.